Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,196Revenue (TTM) $M1,681Net Margin (%)9.2Altman Z-Score2.5
Enterprise Value $M5,312EPS (TTM) $3.2Operating Margin %14.1Piotroski F-Score4
P/E(ttm)27.4Beneish M-Score-2.5Pre-tax Margin (%)13.3Higher ROA y-yN
Price/Book5.010-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales2.55-y EBITDA Growth Rate %9.1Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow17.4y-y EBITDA Growth Rate %22.7ROA % (ttm)6.3Higher Current Ratio y-yN
Dividend Yield %--PEG3.1ROE % (ttm)19.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M47.4ROIC % (ttm)9.3Gross Margin Increase y-yN

Gurus Latest Trades with CRL

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CRL is held by these investors:



CRL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Molho DavideCorporate Executive VP 2017-03-16Sell11,717$90-1.58view
Molho DavideCorporate Executive VP 2017-03-10Sell3,191$89.71-1.26view
JOHST DAVID PCorporate Executive VP 2017-03-10Sell7,307$89.44-0.96view
JOHST DAVID PCorporate Executive VP 2017-03-10Sell34,593$89.06-0.54view
Barbo William DCorporate Executive VP & CCO 2017-03-06Sell12,548$87.780.91view
Barbo William DCorporate Executive VP & CCO 2017-03-06Sell1,900$87.90.77view
Smith David RossCorporate EVP, CFO & CAO 2017-03-03Sell7,750$87.940.73view
Smith David RossCorporate EVP, CFO & CAO 2017-03-03Sell3,890$88.120.52view
BERTOLINI ROBERT JDirector 2017-03-01Sell6,735$880.66view
BERTOLINI ROBERT JDirector 2017-03-01Sell5,255$87.531.2view

Press Releases about CRL :

Quarterly/Annual Reports about CRL:

News about CRL:

Articles On GuruFocus.com
5 Best Stocks for Value Investors This Week - Feb. 25 Feb 26 2017 
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017 
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017 
Bob Olstein's Olstein Strategic Opportunities Fund 2nd Quarter Commentary Sep 01 2016 
Olstein Strategic Opportunities Fund 1st Quarter Letter to Shareholders Jun 07 2016 
Olstein All Cap Value Fund First Quarter Commentary Jun 01 2016 
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 

More From Other Websites
Charles River Labs settles with feds over NIH billing flap Mar 14 2017
Company to pay $1.8M to settle claims of overbilling Mar 13 2017
Company to pay $1.8M to settle claims of overbilling Mar 13 2017
Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory... Mar 13 2017
Charles River Laboratories to Present at Raymond James and Barclays Conferences Mar 06 2017
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials Feb 18 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: 2016 By the Numbers :... Feb 16 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q4, 2016 By the Numbers :... Feb 15 2017
Edited Transcript of CRL earnings conference call or presentation 14-Feb-17 1:00pm GMT Feb 14 2017
Charles River Laboratories International Inc Earnings Call scheduled for 8:00 am ET today Feb 14 2017
Q4 2016 Charles River Laboratories International Inc Earnings Release - Before Market Open Feb 14 2017
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Feb 14 2017
Charles River tops Street 4Q forecasts Feb 14 2017
Charles River tops Street 4Q forecasts Feb 14 2017
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing... Feb 14 2017
Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q Feb 13 2017
Charles River Laboratories Changes Time of Fourth-Quarter 2016 Earnings and 2017 Guidance Conference... Feb 09 2017
Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics Jan 30 2017
John Rogers Comments on Charles River Laboratories Intl Jan 20 2017
John Rogers' Ariel Fund 4th Quarter Commentary Jan 20 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)